Inventiva S.A. (IVA.PA)
EUR 2.82
(-0.53%)
EUR 2.82
(-0.53%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 17.5 Million EUR | 56.47% |
| 2022 | 11.18 Million EUR | 252.03% |
| 2021 | 3.17 Million EUR | 770.25% |
| 2020 | -474 Thousand EUR | -106.77% |
| 2019 | 6.99 Million EUR | 213.81% |
| 2018 | 2.23 Million EUR | -57.8% |
| 2017 | 5.28 Million EUR | -33.6% |
| 2016 | 7.95 Million EUR | 129.4% |
| 2015 | 3.46 Million EUR | 97.22% |
| 2014 | 1.75 Million EUR | 27.26% |
| 2013 | 1.38 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.73 Million EUR | 0.0% |
| 2023 Q2 | 6.16 Million EUR | 0.0% |
| 2023 FY | 17.5 Million EUR | 56.47% |
| 2023 Q4 | 15.98 Million EUR | 0.0% |
| 2022 Q4 | 14.94 Million EUR | 0.0% |
| 2022 Q2 | -454 Thousand EUR | 0.0% |
| 2022 FY | 11.18 Million EUR | 252.03% |
| 2021 Q2 | -394 Thousand EUR | -632.43% |
| 2021 Q1 | 74 Thousand EUR | 127.11% |
| 2021 FY | 3.17 Million EUR | 770.25% |
| 2021 Q4 | 3.49 Million EUR | 0.0% |
| 2020 FY | -474 Thousand EUR | -106.77% |
| 2020 Q1 | 87 Thousand EUR | -98.33% |
| 2020 Q2 | -288 Thousand EUR | -431.03% |
| 2020 Q4 | -273 Thousand EUR | 0.0% |
| 2019 FY | 6.99 Million EUR | 213.81% |
| 2019 Q4 | 5.2 Million EUR | 0.0% |
| 2019 Q2 | 875 Thousand EUR | -49.99% |
| 2019 Q1 | 1.74 Million EUR | -36.17% |
| 2018 Q4 | 2.74 Million EUR | 0.0% |
| 2018 FY | 2.23 Million EUR | -57.8% |
| 2018 Q2 | 3.67 Million EUR | 359.31% |
| 2018 Q1 | 799.25 Thousand EUR | -80.63% |
| 2017 FY | 5.28 Million EUR | -33.6% |
| 2017 Q1 | 1.63 Million EUR | -76.91% |
| 2017 Q2 | 4.82 Million EUR | 195.83% |
| 2017 Q4 | 4.12 Million EUR | 0.0% |
| 2016 Q4 | 7.06 Million EUR | 0.0% |
| 2016 Q2 | 6.22 Million EUR | 163.75% |
| 2016 Q1 | 2.36 Million EUR | -44.82% |
| 2016 FY | 7.95 Million EUR | 129.4% |
| 2015 FY | 3.46 Million EUR | 97.22% |
| 2015 Q4 | 4.27 Million EUR | 251.13% |
| 2015 Q3 | 1.21 Million EUR | -59.05% |
| 2015 Q2 | 2.97 Million EUR | 144.22% |
| 2015 Q1 | 1.21 Million EUR | 0.0% |
| 2014 FY | 1.75 Million EUR | 27.26% |
| 2014 Q2 | 820.73 Thousand EUR | 0.0% |
| 2014 Q1 | 820.73 Thousand EUR | 0.0% |
| 2014 Q3 | 820.73 Thousand EUR | 0.0% |
| 2014 Q4 | 1.21 Million EUR | 48.49% |
| 2013 Q3 | 766.12 Thousand EUR | 0.0% |
| 2013 Q1 | 766.12 Thousand EUR | 0.0% |
| 2013 Q4 | 820.73 Thousand EUR | 7.13% |
| 2013 FY | 1.38 Million EUR | 0.0% |
| 2013 Q2 | 766.12 Thousand EUR | 0.0% |
| 2012 Q4 | 766.12 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -2731.715% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -347.113% |
| Adocia SA | 1.38 Million EUR | -1163.538% |
| Aelis Farma SA | 12.35 Million EUR | -41.609% |
| Biophytis S.A. | -803 Thousand EUR | 2279.328% |
| Advicenne S.A. | 1.42 Million EUR | -1127.209% |
| genOway Société anonyme | 20.1 Million EUR | 12.937% |
| IntegraGen SA | 5.01 Million EUR | -248.725% |
| Medesis Pharma S.A. | -2.66 Million EUR | 756.718% |
| Neovacs S.A. | 29.31 Thousand EUR | -59598.438% |
| NFL Biosciences SA | -56.06 Thousand EUR | 31314.326% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -712.851% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 1333.012% |
| Sensorion SA | 3.78 Million EUR | -362.002% |
| Theranexus Société Anonyme | -4.63 Million EUR | 477.262% |
| TME Pharma N.V. | -127 Thousand EUR | 13879.528% |
| Valbiotis SA | 2.66 Million EUR | -555.922% |
| TheraVet SA | -530.79 Thousand EUR | 3396.935% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -1281.215% |
| DBV Technologies S.A. | 4.15 Million EUR | -320.714% |
| Genfit S.A. | 28.22 Million EUR | 37.996% |
| GeNeuro SA | -293.8 Thousand EUR | 6056.433% |
| Innate Pharma S.A. | -4.12 Million EUR | 524.654% |
| MaaT Pharma SA | 1.65 Million EUR | -957.402% |
| MedinCell S.A. | 9.28 Million EUR | -88.415% |
| Nanobiotix S.A. | 36.2 Million EUR | 51.668% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -685.811% |
| Poxel S.A. | 1000.00 EUR | -1749900.0% |
| GenSight Biologics S.A. | 3 Million EUR | -483.333% |
| Transgene SA | -28.4 Million EUR | 161.611% |
| Valneva SE | 52.83 Million EUR | 66.879% |